# FDA Strengthens U.S. Infant Formula Supply Resilience

On January 10, 2025, the FDA released a long-term strategy to strengthen the resilience of the U.S. infant formula supply chain, building on actions begun in 2023 and a 2024 National Academies study. The strategy prioritizes supply-chain information sharing, contamination prevention, encouraging new manufacturers to enter the market, and improving visibility into supply and shortage risks. It does not announce a solicitation, contract, or new funding, but signals areas that may shape future FDA regulatory, data, and industry-engagement activity.

- Infant formula manufacturers and suppliers can assess how their capacity, contamination-prevention practices, and supply information-sharing capabilities align with the strategy’s stated priorities.
- Procurement professionals should note the strategy as a supply-chain resilience development, not as an open contracting opportunity; no specific procurement vehicle or deadline is identified.
- Companies interested in entering or expanding in the market may find the FDA’s focus on encouraging new manufacturers relevant to their business planning, while recognizing that the strategy does not establish a procurement award or guarantee market access.

**Jurisdictions:** federal
**Industries:** Healthcare
**Published:** November 20, 2026

### Government Entities
- U.S. Food and Drug Administration (FDA)

### Sources
- [FDA Announces Release of Long-Term National Strategy to Increase the Resiliency of the U.S. Infant Formula Market | FDA](https://www.fda.gov/food/fda-updates-food/fda-announces-release-long-term-national-strategy-increase-resiliency-us-infant-formula-market) - F